Sökning: (WFRF:(Nilsson Mats)) pers:(Nilsson Christer)
> (2015-2019) >
Secondary Acute Mye...
-
Nilsson, ChristerKarolinska Institutet,Karolinska Institute,Karolinska Inst, Sweden
(författare)
Secondary Acute Myeloid Leukemia and the Role of Allogeneic Stem Cell Transplantation in a Population-Based Setting
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
-
Elsevier,2019
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:umu-167012
-
https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-167012URI
-
https://doi.org/10.1016/j.bbmt.2019.05.038DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-396629URI
-
https://lup.lub.lu.se/record/407e42e2-4bf7-4f38-a474-7f8c8e5eec69URI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:142065096URI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-161413URI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Funding Agencies|Swedish Cancer Foundation; Stockholm County CouncilStockholm County Council; Gothenburg Medical Society; Assar Gabrielsson Foundation; Swedish Research CouncilSwedish Research Council
-
Secondary AML (s-AML), including AML with an antecedent hematologic disorder (AHD-AML) and therapy-related AML (t-AML), constitutes a large proportion of patients with AML and is considered to confer a dismal prognosis. The role of allogeneic hematopoietic cell transplantation (HCT) in patients with s-AML and the extent to which HCT is performed in these patients has been little studied to date. We used the population-based Swedish AML Registry comprising 3337 intensively treated adult patients over a 17-year period to study the role of HCT within the group of patients with s-AML as well as compared with patients with de novo AML. HCT was performed in 576 patients (22%) with de novo AML, in 74 patients (17%) with AHD-AML, and in 57 patients (20%) with t-AML. At 5 years after diagnosis, there were no survivors among patients with previous myeloproliferative neoplasms who did not undergo HCT, and corresponding survival for patients with antecedent myelodysplastic syndromes and t-AML was and 2% and 4%, respectively. HCT was compared with chemotherapy consolidation in s-AML using 3 models: (1) a 200-day landmark analysis, in which HCT was favorable compared with conventional consolidation (P = .04, log-rank test); (2) a multivariable Cox regression with HCT as a time-dependent variable, in which the hazard ratio for mortality was 0.73 (95% confidence interval, 0.64 to 0.83) for HCT and favored HCT in all subgroups; and (3) a propensity score matching analysis, in which the 5-year overall survival (OS) and relapse-free survival in patients with s-AML in first complete remission (CR1) was 48% and 43%, respectively, for patients undergoing HCT versus 20% and 21%, respectively, for those receiving chemotherapy consolidation (P = .01 and .02, respectively, log-rank test). Our observational data suggest that HCT improves survival and offers the only realistic curative treatment option in patients with s-AML.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Hulegårdh, ErikSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
(författare)
-
Garelius, HegeSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
(författare)
-
Möllgård, LarsSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
(författare)
-
Brune, MatsSahlgrens Univ Hosp, Dept Med, Sect Hematol & Coagulat, Gothenburg, Sweden,Sahlgrenska University Hospital
(författare)
-
Wahlin, AndersUmeå University,Umeå universitet,Onkologi,Univ Umea, Dept Radiat Sci, Umea, Sweden(Swepub:umu)anwa0027
(författare)
-
Lenhoff, StigLund University,Lunds universitet,Avdelningen för hematologi och transfusionsmedicin,Institutionen för laboratoriemedicin,Medicinska fakulteten,Division of Hematology and Transfusion Medicine,Department of Laboratory Medicine,Faculty of Medicine,Skåne University Hospital,Lund Univ, Sweden(Swepub:lu)med-slf
(författare)
-
Frödin, UllaLinköpings universitet,Linköping University,Institutionen för medicin och hälsa,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US(Swepub:liu)n/a
(författare)
-
Remberger, MatsKarolinska Inst, Dept Oncol Pathol, Stockholm, Sweden,Karolinska University Hospital
(författare)
-
Höglund, MartinUppsala University,Uppsala universitet,Hematologi,Uppsala Univ, Sweden(Swepub:uu)martinhl
(författare)
-
Juliusson, GunnarLund University,Lunds universitet,Stamcellscentrum (SCC),Avdelningen för stamcellsforskning,Institutionen för laboratoriemedicin,Medicinska fakulteten,Stem Cell Center,Division of stem cell research,Department of Laboratory Medicine,Faculty of Medicine,Lund Univ, Sweden(Swepub:lu)stem-gju
(författare)
-
Stockelberg, DickSodra Alvsborgs Hosp, Dept Med & Oncol, Boras, Sweden,South Elfsborg Hospital
(författare)
-
Lehmann, SörenKarolinska Institutet,Uppsala University,Karolinska Institute,Karolinska Inst, Sweden; Uppsala Univ, Sweden
(författare)
-
Karolinska InstitutetKarolinska Institute
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Biology of blood and marrow transplantation: Elsevier25:9, s. 1770-17781083-87911523-6536
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Nilsson, Christe ...
-
Hulegårdh, Erik
-
Garelius, Hege
-
Möllgård, Lars
-
Brune, Mats
-
Wahlin, Anders
-
visa fler...
-
Lenhoff, Stig
-
Frödin, Ulla
-
Remberger, Mats
-
Höglund, Martin
-
Juliusson, Gunna ...
-
Stockelberg, Dic ...
-
Lehmann, Sören
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Hematologi
- Artiklar i publikationen
-
Biology of blood ...
- Av lärosätet
-
Umeå universitet
-
Uppsala universitet
-
Lunds universitet
-
Karolinska Institutet
-
Linköpings universitet